Bayer Résultats passés
Passé contrôle des critères 0/6
Bayer a connu une croissance annuelle moyenne de ses bénéfices de 1%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 8.5% par an. Les revenus ont augmenté de en hausse à un taux moyen de 0.9% par an.
Informations clés
0.96%
Taux de croissance des bénéfices
0.96%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 7.33% |
| Taux de croissance des recettes | 0.87% |
| Rendement des fonds propres | -7.36% |
| Marge nette | -4.77% |
| Prochaine mise à jour des résultats | 04 Aug 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jul 08
BAYN: Litigation Ruling And Settlement Progress Will Drive Future Re Rating
The analyst price target for Bayer has been revised higher from €60.00 to €63.81 as analysts factor in recent upgrades tied to progress on glyphosate litigation and mixed, but generally more constructive, Street research. Analyst Commentary Recent Street research on Bayer has turned more constructive, with several bullish analysts highlighting progress on glyphosate litigation and updated views on the company's pharmaceutical outlook.Mise à jour du récit • Jun 24
BAYN: Litigation Progress And Key Approvals Will Drive Future Re Rating
Analysts nudged their average price target for Bayer slightly higher to about €40.50, citing updated views on litigation risks, the outlook for the asundexian pipeline, and recent recalibrations of valuation multiples such as forward P/E. Analyst Commentary Recent Street research around Bayer highlights a mixed but gradually improving tone, with several bullish analysts adjusting price targets and ratings as they reassess litigation exposure, the asundexian opportunity, and the conglomerate discount.Article d’analyse • Jun 16
Bayer (XTRA:BAYN) Stock Could Be 9.2% Undervalued After FDA Approval Of AMBELVIST
Bayer (XTRA:BAYN) is back in focus after the U.S. FDA approved AMBELVIST, a macrocyclic gadolinium based contrast agent for contrast enhanced MRI in adults and pediatric patients, including term neonates. See our latest analysis for Bayer. Despite recent product and leadership announcements, Bayer’s 1 year total shareholder return of 32.05% contrasts with a 5 year total shareholder return that is down 24.26%, while its 90 day share price return is down 9.7%. This suggests longer term holders...Mise à jour du récit • Jun 06
BAYN: Litigation Resolution And Key Drug Approvals Will Drive Future Re Rating
Narrative Update on Bayer Analysts have lifted Bayer's blended price target to €40, with many highlighting higher published targets from firms such as DZ Bank, Deutsche Bank, Jefferies and UBS. They are still pointing to litigation outcomes and the asundexian data readout as key swing factors.Mise à jour du récit • May 22
BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential
Analysts have maintained the fair value estimate for Bayer at €60.00 and raised price targets in recent research, citing a series of upgrades, slightly higher assumptions for revenue growth and profit margins, as well as a modestly lower future P/E multiple following a broad reassessment of sector risks and company-specific legal developments. Analyst Commentary Recent research points to a clear shift toward more constructive views on Bayer, with several bullish analysts updating ratings and valuation frameworks in response to company specific developments and sector wide reassessments.
Mise à jour du récit • May 05
BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential
Analysts have nudged the fair value estimate for Bayer higher to about €31.26 from €30.41, citing a series of recent upgrades and higher price targets that reflect updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Bayer has been mixed, with several firms updating ratings and price targets over the past few months.Mise à jour du récit • Apr 21
BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential
Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.Mise à jour du récit • Apr 06
BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside
Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.Mise à jour du récit • Mar 23
BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings
Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.Mise à jour du récit • Mar 09
BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings
Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.Mise à jour du récit • Feb 23
BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside
The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.Mise à jour du récit • Feb 09
BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside
Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.Article d’analyse • Jan 27
The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More
Despite an already strong run, Bayer Aktiengesellschaft ( ETR:BAYN ) shares have been powering on, with a gain of 29...Mise à jour du récit • Jan 25
BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside
Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.
Mise à jour du récit • Jan 09
BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares
Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.Mise à jour du récit • Dec 26
BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential
Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.Mise à jour du récit • Dec 11
BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares
Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.Article d’analyse • Dec 03
Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce
Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders have had their patience rewarded with a 27% share price jump in the...Mise à jour du récit • Nov 27
BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares
Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.Article d’analyse • Nov 14
Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a pretty great week for Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders, with its shares surging 13% to...Mise à jour du récit • Nov 13
BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum
Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Bayer gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 45,242 | -2,156 | 16,012 | 5,611 |
| 31 Dec 25 | 45,575 | -3,620 | 16,023 | 5,650 |
| 30 Sep 25 | 45,866 | -198 | 15,818 | 5,854 |
| 30 Jun 25 | 46,174 | -3,418 | 16,689 | 6,088 |
| 31 Mar 25 | 46,579 | -3,253 | 16,643 | 6,006 |
| 31 Dec 24 | 46,606 | -2,552 | 16,764 | 5,974 |
| 30 Sep 24 | 46,739 | -880 | 16,264 | 5,553 |
| 30 Jun 24 | 47,113 | -1,266 | 15,984 | 5,277 |
| 31 Mar 24 | 47,013 | -3,119 | 15,778 | 5,225 |
| 31 Dec 23 | 47,637 | -2,941 | 16,002 | 5,370 |
| 30 Sep 23 | 47,775 | -3,667 | 14,881 | 5,511 |
| 30 Jun 23 | 48,714 | 1,448 | 15,565 | 6,175 |
| 31 Mar 23 | 50,489 | 3,037 | 16,143 | 6,285 |
| 31 Dec 22 | 50,739 | 4,150 | 16,036 | 6,168 |
| 30 Sep 22 | 49,857 | 4,700 | 15,993 | 5,884 |
| 30 Jun 22 | 48,357 | 4,239 | 15,413 | 5,681 |
| 31 Mar 22 | 46,392 | 2,202 | 14,936 | 5,582 |
| 31 Dec 21 | 44,081 | 1,000 | 14,531 | 5,326 |
| 30 Sep 21 | 42,958 | 222 | 12,479 | 3,449 |
| 30 Jun 21 | 41,683 | -7,565 | 13,772 | 5,010 |
| 31 Mar 21 | 40,883 | -14,849 | 13,524 | 4,780 |
| 31 Dec 20 | 41,400 | -15,569 | 13,886 | 4,884 |
| 30 Sep 20 | 42,155 | -15,995 | 15,174 | 7,215 |
| 30 Jun 20 | 43,479 | -7,303 | 13,820 | 5,100 |
| 31 Mar 20 | 44,138 | 2,631 | 14,594 | 5,267 |
| 31 Dec 19 | 43,545 | 2,391 | 14,801 | 5,282 |
| 30 Sep 19 | 43,150 | -1,530 | 15,360 | 5,196 |
| 30 Jun 19 | 42,581 | 287 | 15,241 | 5,082 |
| 31 Mar 19 | 39,856 | 557 | 14,366 | 4,978 |
| 31 Dec 18 | 36,742 | 1,374 | 13,238 | 4,701 |
| 30 Sep 18 | 34,983 | 6,027 | 13,276 | 4,525 |
| 30 Jun 18 | 33,747 | 3,237 | 12,480 | 4,434 |
| 31 Mar 18 | 34,473 | 3,486 | 12,579 | 4,254 |
| 31 Dec 17 | 35,015 | 3,249 | 12,689 | 4,272 |
| 30 Sep 17 | 35,242 | 3,087 | 12,878 | 4,381 |
| 30 Jun 17 | 35,475 | 3,924 | 12,949 | 4,347 |
| 31 Mar 17 | 32,769 | 3,991 | 12,448 | 4,305 |
| 31 Dec 16 | 34,943 | 3,743 | 12,686 | 4,321 |
| 30 Sep 16 | 37,405 | 3,837 | 12,959 | 4,299 |
| 30 Jun 16 | 40,151 | 3,971 | 13,327 | 4,291 |
| 31 Mar 16 | 46,146 | 4,210 | 14,110 | 4,339 |
| 31 Dec 15 | 46,085 | 4,025 | 14,250 | 4,207 |
| 30 Sep 15 | 45,592 | 3,616 | 14,145 | 4,020 |
Des revenus de qualité: BAYN n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: BAYN n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: BAYN n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 1% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de BAYN au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: BAYN n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( 15.1% ).
Rendement des fonds propres
ROE élevé: BAYN a un retour sur capitaux propres négatif ( -7.36% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/21 17:39 |
| Cours de l'action en fin de journée | 2026/07/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bayer Aktiengesellschaft est couverte par 40 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Emily Field | Barclays |
| Charles Pitman | Barclays |